{"id":"https://openalex.org/W2043766038","doi":"https://doi.org/10.1016/0014-2999(82)90091-7","title":"Choline and physostigmine enhance haloperidol-induced HVA and DOPAC accumulation","display_name":"Choline and physostigmine enhance haloperidol-induced HVA and DOPAC accumulation","publication_year":1982,"publication_date":"1982-06-01","ids":{"openalex":"https://openalex.org/W2043766038","doi":"https://doi.org/10.1016/0014-2999(82)90091-7","mag":"2043766038","pmid":"https://pubmed.ncbi.nlm.nih.gov/7106193"},"language":"en","primary_location":{"id":"doi:10.1016/0014-2999(82)90091-7","doi":"https://doi.org/10.1016/0014-2999(82)90091-7","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(82)90091-7","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111986257","display_name":"William R. Millington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I63966007","display_name":"Massachusetts Institute of Technology","ror":"https://ror.org/042nb2s44","country_code":"US","type":"education","lineage":["https://openalex.org/I63966007"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William R. Millington","raw_affiliation_strings":["Laboratory of Neuroendocrine Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Neuroendocrine Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, U.S.A","institution_ids":["https://openalex.org/I63966007"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109899809","display_name":"Richard Jay Wurtman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I63966007","display_name":"Massachusetts Institute of Technology","ror":"https://ror.org/042nb2s44","country_code":"US","type":"education","lineage":["https://openalex.org/I63966007"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard J. Wurtman","raw_affiliation_strings":["Laboratory of Neuroendocrine Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Neuroendocrine Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, U.S.A","institution_ids":["https://openalex.org/I63966007"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I63966007"],"apc_list":{"value":3230,"currency":"USD","value_usd":3230},"apc_paid":null,"fwci":0.5613,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.56122564,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"4","first_page":"431","last_page":"434"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9291999936103821,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9291999936103821,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.051899999380111694,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/choline","display_name":"choline","score":0.8859999775886536},{"id":"https://openalex.org/keywords/physostigmine","display_name":"physostigmine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":1.0},{"id":"https://openalex.org/keywords/homovanillic-acid","display_name":"homovanillic acid","score":0.9330000281333923},{"id":"https://openalex.org/keywords/dopac","display_name":"DOPAC","score":0.9729999899864197},{"id":"https://openalex.org/keywords/dopamine-turnover","display_name":"dopamine turnover","score":0.7919999957084656},{"id":"https://openalex.org/keywords/nigrostriatal-neurons","display_name":"nigrostriatal neurons","score":0.9319999814033508},{"id":"https://openalex.org/keywords/dopamine-receptor-blockade","display_name":"dopamine receptor blockade","score":0.8080000281333923},{"id":"https://openalex.org/keywords/cholinergic-agonists","display_name":"cholinergic agonists","score":0.8579999804496765},{"id":"https://openalex.org/keywords/neuronal-firing-rate","display_name":"neuronal firing rate","score":0.7870000004768372},{"id":"https://openalex.org/keywords/striatum","display_name":"striatum","score":0.7400000095367432}],"concepts":[{"id":"https://openalex.org/C2776663719","wikidata":"https://www.wikidata.org/wiki/Q410595","display_name":"Physostigmine","level":3,"score":0.8681766986846924},{"id":"https://openalex.org/C2775841634","wikidata":"https://www.wikidata.org/wiki/Q903566","display_name":"Homovanillic acid","level":4,"score":0.8337653875350952},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.8055948615074158},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.7254530191421509},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6002734899520874},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.58524489402771},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5815932154655457},{"id":"https://openalex.org/C22885893","wikidata":"https://www.wikidata.org/wiki/Q4862743","display_name":"Cholinergic","level":2,"score":0.5739192962646484},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.5215863585472107},{"id":"https://openalex.org/C2781353949","wikidata":"https://www.wikidata.org/wiki/Q3271533","display_name":"Dopamine antagonist","level":4,"score":0.5195930004119873},{"id":"https://openalex.org/C2775905480","wikidata":"https://www.wikidata.org/wiki/Q4634071","display_name":"3,4-Dihydroxyphenylacetic acid","level":5,"score":0.41466063261032104},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.41325628757476807},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3752632439136505},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2447153925895691},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2171051800251007},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.05956491827964783}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002794","descriptor_name":"Choline","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003342","descriptor_name":"Corpus Striatum","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006719","descriptor_name":"Homovanillic Acid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010648","descriptor_name":"Phenylacetates","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D010830","descriptor_name":"Physostigmine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011919","descriptor_name":"Rats, Inbred Strains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015102","descriptor_name":"3,4-Dihydroxyphenylacetic Acid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0014-2999(82)90091-7","doi":"https://doi.org/10.1016/0014-2999(82)90091-7","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(82)90091-7","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:7106193","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7106193","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8371999859809875}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W806773598","https://openalex.org/W1972262870","https://openalex.org/W1973719823","https://openalex.org/W1987990885","https://openalex.org/W2010924124","https://openalex.org/W2029163869","https://openalex.org/W2054213050","https://openalex.org/W2056859594","https://openalex.org/W2147316433","https://openalex.org/W2159996636"],"related_works":["https://openalex.org/W2085764035","https://openalex.org/W2026396624","https://openalex.org/W2059714559","https://openalex.org/W2033239660","https://openalex.org/W2075875703","https://openalex.org/W151626155","https://openalex.org/W2041838486","https://openalex.org/W654986648","https://openalex.org/W2019516846","https://openalex.org/W2256470976"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}